DescriptionCurator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/50168slr078_cotisporin_lbl.pdf
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/50168slr078_cotisporin_lbl.pdf
Bacitracin is a polypeptide antibiotic produced by Bacillus subtilis and Bacillus licheniformis. Bacitracin in combination with neomycin and polymyxin B is indicated for the treatment of many bacterial diseases. The antibacterial properties of bacitracin are mediated by its binding to C55-isoprenyl pyrophosphate, resulting in inhibition of cell wall biosynthesis.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2364036 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | BACITRACIN Approved UseUses first aid to help prevent infection in: •minor cuts •scrapes •burns Launch Date1948 |
|||
Curative | CORTISPORIN Approved UseFor the treatment of corticosteroid-responsice dermatoses with secondary infection. Launch Date1957 |
|||
Curative | NEOSPORIN Approved UseNEOSPORIN Ophthalmic Ointment is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis. Launch Date1968 |
PubMed
Title | Date | PubMed |
---|---|---|
Bacitracin: Methods of Production, Concentration, and Partial Purification, with a Summary of the Chemical Properties of Crude Bacitracin. | 1948 Feb |
|
The relative antisyphilitic activity of penicillins F,G,K, and X and of bacitracin, based on the amounts required to abort early syphilic infections in rabbits. | 1948 Mar |
|
The Action of Bacitracin and Subtilin on Treponema pallidum in Vitro and in Vivo. | 1948 Mar |
|
The Results of the Systemic Administration of the Antibiotic, Bacitracin, in Surgical Infections: A Preliminary Report. | 1948 Oct |
|
A Note on the Susceptibility of Hemophilus influenzae Type B to Bacitracin. | 1948 Oct |
|
The Use of Bacitracin in Experimental Clostridium Welchii Infection in Guinea Pigs. | 1949 Oct |
|
IN VITRO STUDIES ON POSSIBLE SYNERGISTIC ACTION BETWEEN PENICILLIN AND BACITRACIN. | 1949 Sep |
|
In vitro sensitivity of Bacillus proteus and Pseudomonas aeruginosa to seven antibiotics; penicillin, streptomycin, bacitracin, polymyxin, aerosporin, aureomycin, and chloromycetin. | 1950 Feb |
|
Systemic bacitracin in the treatment of progressive bacterial synergistic gangrene. | 1950 Feb |
|
Continuous administration of growth hormone does not prevent the decrease of IGF-I gene expression in zinc-deprived rats despite normalization of liver GH binding. | 1998 Dec |
|
Copper transport and its defect in Wilson disease: characterization of the copper-binding domain of Wilson disease ATPase. | 2000 Apr |
|
Individual variability in the zinc inducibility of metallothionein-IIA mRNA in human lymphocytes. | 2000 Dec 15 |
|
Defective antioxidant defense system in patients with a human leptin gene mutation. | 2000 Jul |
|
Reduction of oxidative stress and cytokine-induced neutrophil chemoattractant (CINC) expression by red wine polyphenols in zinc deficiency induced intestinal damage of rat. | 2000 Jun 1 |
|
Therapeutic application of zinc in human immunodeficiency virus against opportunistic infections. | 2000 May |
|
Effect of the two conserved prolines of human growth inhibitory factor (metallothionein-3) on its biological activity and structure fluctuation: comparison with a mutant protein. | 2000 Nov 28 |
|
Dietary zinc deficiency increases uroguanylin accumulation in rat kidney. | 2001 Apr |
|
Metallothionein isogene transcription in red blood cell precursors from human cord blood. | 2001 Feb |
|
Coexistence of zinc and iron augmented oxidative injuries in the nigrostriatal dopaminergic system of SD rats. | 2001 Feb 1 |
|
Nitric oxide induces metallothionein (MT) gene expression apparently by displacing zinc bound to MT. | 2001 Feb 28 |
|
Arsenite-inducible RNA-associated protein (AIRAP) protects cells from arsenite toxicity. | 2001 Jan |
|
Tyrphostin [correction of Tryphostin] AG879, a tyrosine kinase inhibitor: prevention of transcriptional activation of the electrophile and the aromatic hydrocarbon response elements. | 2001 Jan 15 |
|
The human ZIP1 transporter mediates zinc uptake in human K562 erythroleukemia cells. | 2001 Jun 22 |
|
Cleavage of SNAP-25 by botulinum toxin type A requires receptor-mediated endocytosis, pH-dependent translocation, and zinc. | 2001 Mar |
|
p38 activation is required upstream of potassium current enhancement and caspase cleavage in thiol oxidant-induced neuronal apoptosis. | 2001 May 15 |
|
Loss of vesicular zinc and appearance of perikaryal zinc after seizures induced by pilocarpine. | 2001 May 25 |
|
Oxidative impairment in scrapie-infected mice is associated with brain metals perturbations and altered antioxidant activities. | 2001 Nov |
|
Influence of dietary zinc deficiency during development on hepatic CYP2C11, CYP2C12, CYP3A2, CYP3A9, and CYP3A18 expression in postpubertal male rats. | 2001 Nov 1 |
|
Zinc deficiency reduces leptin gene expression and leptin secretion in rat adipocytes. | 2001 Oct |
|
Metallothionein is required for zinc-induced expression of the macrophage colony stimulating factor gene. | 2002 |
|
Src-dependent phosphorylation of the epidermal growth factor receptor on tyrosine 845 is required for zinc-induced Ras activation. | 2002 Jul 5 |
|
Partitioning of accumulated trace metals in the talitrid amphipod crustacean Orchestia gammarellus: a cautionary tale on the use of metallothionein-like proteins as biomarkers. | 2002 Jun |
|
Co-assembly of GABA rho subunits with the GABA(A) receptor gamma(2) subunit cloned from white perch retina. | 2002 Jun 30 |
|
Zinc enhances the expression of interleukin-2 and interleukin-2 receptors in HUT-78 cells by way of NF-kappaB activation. | 2002 Oct |
|
Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). | 2002 Oct 25 |
|
Evidence for non-isostructural replacement of Zn(2+) with Cd(2+) in the beta-domain of brain-specific metallothionein-3. | 2002 Sep 11 |
|
Induction of metallothionein by zinc protects from daunorubicin toxicity in rats. | 2002 Sep 30 |
|
Interrelationships among brain, endocrine and immune response in ageing and successful ageing: role of metallothionein III isoform. | 2003 Apr |
|
Effect of chromium on apolipoprotein A-I expression in HepG2 cells. | 2003 Apr |
|
Changes in rat hepatic gene expression in response to zinc deficiency as assessed by DNA arrays. | 2003 Apr |
|
The acrodermatitis enteropathica gene ZIP4 encodes a tissue-specific, zinc-regulated zinc transporter in mice. | 2003 Aug 29 |
|
Human peptidoglycan recognition protein-L is an N-acetylmuramoyl-L-alanine amidase. | 2003 Dec 5 |
|
Chromium(VI) down-regulates heavy metal-induced metallothionein gene transcription by modifying transactivation potential of the key transcription factor, metal-responsive transcription factor 1. | 2003 Jul 11 |
|
In vitro effect of metal ions on the activity of two amphibian glyceraldehyde-3-phosphate dehydrogenases: potential metal binding sites. | 2003 Jun |
|
Zinc accumulation in N-methyl-N-nitrosourea-induced rat mammary tumors is accompanied by an altered expression of ZnT-1 and metallothionein. | 2003 Jun |
|
Interaction of Tl+ with product complexes of fructose-1,6-bisphosphatase. | 2003 May 2 |
|
Zinc modulates PPARgamma signaling and activation of porcine endothelial cells. | 2003 Oct |
|
Prion, amyloid beta-derived Cu(II) ions, or free Zn(II) ions support S-nitroso-dependent autocleavage of glypican-1 heparan sulfate. | 2003 Oct 3 |
|
Thymulin evokes IL-6-C/EBPbeta regenerative repair and TNF-alpha silencing during endotoxin exposure in fetal lung explants. | 2004 Mar |
|
Bacitracin Inhibits the Migration of U87-MG Glioma Cells via Interferences of the Integrin Outside-in Signaling Pathway. | 2016 Mar |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/50168slr078_cotisporin_lbl.pdf
Curator's Comment: Bacitracin can be used as ophtalmic solution (0.025mg/ml) for the treatment of superficial ocular infections.
400 units, topically
Route of Administration:
Topical
Substance Class |
Mixture
Created
by
admin
on
Edited
Wed Apr 02 09:38:17 GMT 2025
by
admin
on
Wed Apr 02 09:38:17 GMT 2025
|
Record UNII |
58H6RWO52I
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Related Record | Type |
---|
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
1284
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
||
|
WHO-VATC |
QR02AB04
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
||
|
WHO-ATC |
J01XX10
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
||
|
CFR |
21 CFR 333.120
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
||
|
CFR |
21 CFR 524.155
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
||
|
WHO-ATC |
R02AB04
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
||
|
CFR |
21 CFR 556.70
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
||
|
EPA PESTICIDE CODE |
6302
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
||
|
CFR |
21 CFR 333.110
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
||
|
CFR |
21 CFR 524.154
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
||
|
CFR |
21 CFR 520.154
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
||
|
WHO-ATC |
D06AX05
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
||
|
WHO-VATC |
QJ01XX10
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
||
|
WHO-VATC |
QD06AX05
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
||
|
WHO-VATC |
QA07AA93
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
BACITRACIN
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | |||
|
100000092135
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | |||
|
215-786-2
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | |||
|
755905
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | |||
|
SUB00652MIG
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | |||
|
1291
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | RxNorm | ||
|
BACITRACIN
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | Description: A white or pale brownish yellow powder; odourless or with a faint characteristic odour. Solubility: Freely soluble in water, methanol R and ethanol (~750 g/l) TS; practically insoluble in acetone R and ether R. Category: Antiinfective drug. Storage: Bacitracin should be kept in a tightly closed container, protected from light and stored at a temperature between 2? and8?C. If it is intended for parenteral administration, the container should be sterile and sealed so as to exclude micro-organisms. Labelling: The designation sterile Bacitracin indicates that the substance complies with the additional requirements for sterileBacitracin and may be used for parenteral administration or for other sterile applications. Additional information: Bacitracin is hygroscopic. Its solutions deteriorate rapidly at room temperature. Even in the absence oflight, it is gradually degraded on exposure to a humid atmosphere, the decomposition being faster at higher temperatures. | ||
|
DB00626
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | |||
|
58H6RWO52I
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | |||
|
C295
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | |||
|
1167
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | |||
|
m2197
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | Merck Index | ||
|
N0000008479
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | Decreased Cell Wall Synthesis & Repair [PE] | ||
|
Bacitracin
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | |||
|
58H6RWO52I
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | |||
|
D001414
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | |||
|
1405-87-4
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | |||
|
CHEMBL1200558
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | |||
|
281
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | |||
|
28669
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY |
All of the following components must be present:
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
MIC
|
||
|
TARGET -> INHIBITOR | |||
|
SALT/SOLVATE -> PARENT | |||
|
SUB_CONCEPT->SUBSTANCE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
sum of impurities L and N: maximum 8.0 per cent
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
sum of impurities L and N: maximum 8.0 per cent
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
sum of impurities F and G: maximum 2.0 per cent
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
sum of impurities O, P and Q: maximum 2.5 per cent
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
sum of impurities F and G: maximum 2.0 per cent
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
sum of impurities O, P and Q: maximum 2.5 per cent
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
sum of impurities O, P and Q: maximum 2.5 per cent
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
http://apps.who.int/phint/pdf/b/Jb.6.1.40.pdf
|